8 research outputs found
Genetic screening in early-onset Alzheimer's disease identified three novel presenilin mutations
Mutations in presenilin 1 (PSEN1), presenilin 2 (PSEN2), and amyloid precursor protein (APP) are major genetic causes of early-onset Alzheimer's disease (EOAD). Clinical heterogeneity is frequently observed in patients with PSEN1 and PSEN2 mutations. Using whole exome sequencing, we screened a Dutch cohort of 68 patients with EOAD for rare variants in Mendelian Alzheimer's disease, frontotemporal dementia, and prion disease genes. We identified 3 PSEN1 and 2 PSEN2 variants. Three variants, 1 in PSEN1 (p.H21Profs*2) and both PSEN2 (p.A415S and p.M174I), were novel and absent in control exomes. These novel variants can be classified as probable pathogenic, except for PSEN1 (p.H21Profs*2) in which the pathogenicity is uncertain. The initial clinical symptoms between mutation carriers varied from behavioral problems to memory impairment. Our findings extend the mutation spectrum of EOAD and underline the clinical heterogeneity among PSEN1 and PSEN2 mutation carriers. Screening for Alzheimer's disease–causing genes is indicated in presenile dementia with an overlapping clinical diagnosis
Differential insular cortex subregional vulnerability to alpha-synuclein pathology in Parkinson's disease and dementia with Lewy bodies
Aim: The insular cortex consists of a heterogenous
cytoarchitecture and diverse connections and is
thought to integrate autonomic, cognitive, emotional
and interoceptive functions to guide behaviour. In
Parkinson’s disease (PD) and dementia with Lewy bodies (DLB), it reveals a-synuclein pathology in advanced
stages. The aim of this study is to assess the insular
cortex cellular and subregional vulnerability to a-synuclein pathology in well-characterized PD and DLB subjects. Methods: We analysed postmortem insular tissue
from 24 donors with incidental Lewy body disease, PD,
PD with dementia (PDD), DLB and age-matched controls. The load and distribution of a-synuclein pathology and tyrosine hydroxylase (TH) cells were studied
throughout the insular subregions. The selective
involvement of von Economo neurons (VENs) in the
anterior insula and astroglia was assessed in all groups.
Results: A decreasing gradient of a-synuclein pathology
load from the anterior periallocortical agranular towards
the intermediate dysgranular and posterior isocortical
granular insular subregions was found. Few VENs
revealed a-synuclein inclusions while astroglial synucleinopathy was a predominant feature in PDD and DLB.
TH neurons were predominant in the agranular and dysgranular subregions but did not reveal a-synuclein inclusions or significant reduction in density in patient
groups. Conclusions: Our study highlights the vulnerability of the anterior agranular insula to a-synuclein
pathology in PD, PDD and DLB. Whereas VENs and
astrocytes were affected in advanced disease stages, insular TH neurons were spared. Owing to the anterior insula’s affective, cognitive and autonomic functions, its
greater vulnerability to pathology indicates a potential
contribution to nonmotor deficits in PD and DLB
Pathologically confirmed autoimmune encephalitis in suspected Creutzfeldt-Jakob disease
Objective: To determine the clinical features and presence in CSF of antineuronal antibodies in patients with pathologically proven autoimmune encephalitis derived from a cohort of patients with suspected Creutzfeldt-Jakob disease (CJD). Methods: The Dutch Surveillance Centre for Prion Diseases performed 384 autopsies on patients with suspected CJD over a 14-year period (1998-2011). Clinical information was collected from treating physicians. Antineuronal antibodies were tested in CSF obtained postmortem by immunohistochemistry on fresh frozen rat brain sections, by Luminex assay for the presence of wellcharacterized onconeural antibodies, and by cell-based assays for antibodies against NMDAR, GABABR1/2, GABAAR GLUR1/2, LGI1, Caspr2, and DPPX. Results: In 203 patients, a diagnosis of definite CJD was made, while in 181 a variety of other conditions were diagnosed, mainly neurodegenerative. In 22 of these 181, the neuropathologist diagnosed autoimmune encephalitis. One patient was excluded because of lack of clinical information. Inflammator
Clusters of co-abundant proteins in the brain cortex associated with fronto-temporal lobar degeneration
Background:
\nFrontotemporal lobar degeneration (FTLD) is characterized pathologically by neuronal and glial inclusions of hyperphosphorylated tau or by neuronal cytoplasmic inclusions of TDP43. This study aimed at deciphering the molecular mechanisms leading to these distinct pathological subtypes.
\n
\nMethods:
\nTo this end, we performed an unbiased mass spectrometry-based proteomic and systems-level analysis of the middle frontal gyrus cortices of FTLD-tau (n = 6), FTLD-TDP (n = 15), and control patients (n = 5). We validated these results in an independent patient cohort (total n = 24).
\n
\nResults:
\nThe middle frontal gyrus cortex proteome was most significantly altered in FTLD-tau compared to controls (294 differentially expressed proteins at FDR = 0.05). The proteomic modifications in FTLD-TDP were more heterogeneous (49 differentially expressed proteins at FDR = 0.1). Weighted co-expression network analysis revealed 17 modules of co-regulated proteins, 13 of which were dysregulated in FTLD-tau. These modules included proteins associated with oxidative phosphorylation, scavenger mechanisms, chromatin regulation, and clathrin-mediated transport in both the frontal and temporal cortex of FTLD-tau. The most strongly dysregulated subnetworks identified cyclin-dependent kinase 5 (CDK5) and polypyrimidine tract-binding protein 1 (PTBP1) as key players in the disease process. Dysregulation of 9 of these modules was confirmed in independent validation data sets of FLTD-tau and control temporal and frontal cortex (total n = 24). Dysregulated modules were primarily associated with changes in astrocyte and endothelial cell protein abundance levels, indicating pathological changes in FTD are not limited to neurons.
\n
\nConclusions:
\nUsing this innovative workflow and zooming in on the most strongly dysregulated proteins of the identified modules, we were able to identify disease-associated mechanisms in FTLD-tau with high potential as biomarkers and/or therapeutic targets
EIF2AK3 variants in Dutch patients with Alzheimer's disease
Next-generation sequencing has contributed to our understanding of the genetics of Alzheimer's disease (AD) and has explained a substantial part of the missing heritability of familial AD. We sequenced 19 exomes from 8 Dutch families with a high AD burden and identified EIF2AK3, encoding for protein kinase RNA-like endoplasmic reticulum kinase (PERK), as a candidate gene. Gene-based burden analysis in a Dutch AD exome cohort containing 547 cases and 1070 controls showed a significant association of EIF2AK3 with AD (OR 1.84 [95% CI 1.07–3.17], p-value 0.03), mainly driven by the variant p.R240H. Genotyping of this variant in an additional cohort from the Rotterdam Study showed a trend toward association with AD (p-value 0.1). Immunohistochemical staining with pPERK and peIF2α of 3 EIF2AK3 AD carriers showed an increase in hippocampal neuronal cells expressing these proteins compared with nondemented controls, but no difference was observed in AD noncarriers. This study suggests that rare variants in EIF2AK3 may be associated with disease risk in AD
Distinctive pattern of temporal atrophy in patients with frontotemporal dementia and the I383V variant in TARDBP
Introduction
Frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS) are closely related disorders, linked pathologically and g